0.285  -0.005 (-1.66%)		03-05 16:00
Open: 0.3 High: 0.3098 Volume: 404,929		Pre. Close: 0.2898 Low: 0.285 Market Cap: 27(M)

Short term
Mid term
Targets	6-month :	0.37	1-year :	0.43
Resists	First :	0.31	Second :	0.37
Pivot price	0.27
Supports	First :	0.27	Second :	0.23
MAs	MA(5) :	0.28	MA(20) :	0.26
	MA(100) :	0.31	MA(250) :	0.33
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	59.2	D(3) :	59.5
RSI	RSI(14): 54.8
52-week	High :	0.5	Low :	0.23

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IGC ] has closed below upper band by 25.7%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.31 - 0.31	0.31 - 0.31
Low:	0.28 - 0.28	0.28 - 0.28
Close:	0.28 - 0.29	0.29 - 0.29

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Thu, 26 Feb 2026
Inside IGC Pharma’s AI push to clean up Alzheimer’s data - Stock Titan

Thu, 26 Feb 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Nasdaq

Tue, 24 Feb 2026
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Tue, 24 Feb 2026
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - Nasdaq

Tue, 24 Feb 2026
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance

Mon, 23 Feb 2026
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Times Argus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.